Case report and literature review: Therapy-related myelodysplastic syndrome/acute myeloid leukemia with del(7)(q22) in a patient with de novo AML

Annals of Clinical and Laboratory Science

Volumn 41, Issue 1, 2011, Pages 79-83

  Kim, Yang Gyun ^a   Cho, Sun Young ^a   Park, Tae Sung ^a   Oh, Seung Hwan ^b   Yoon, Hwi Joong ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER REGRESSION; CASE REPORT; CHROMOSOME 7Q; CHROMOSOME DELETION; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; KARYOTYPE 46,XX; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; BONE MARROW; CHROMOSOME 7; FATALITY; FOLLOW UP; GENETICS; KARYOTYPING; MIDDLE AGED; PATHOLOGY; SECOND CANCER;

ANTINEOPLASTIC AGENTS; BONE MARROW; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 7; FATAL OUTCOME; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY;

EID: 79951894749     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008;35:418-429.
2. Arana-Yi C, Block AMW, Sait SN, Ford LA, Barcos M, Baer MR. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeoid leukemia: Possible role of cytarabine. Leukemia Res 2008;32:1043-1048.
3. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99: 1909-1912. (Pubitemid 34525468)
4. Ogasawara T, Yasuyama M, Kawauchi K. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2). Am J Hematol 2005;79:136-141. (Pubitemid 40770673)
5. Seiter K, Feldman EJ, Sreekantaiah C, Pozzuoli M, Weisberger J, Liu D, Papageorgio C, Weiss M, Kancherla R, Ahmed T. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 2001;15:963-970. (Pubitemid 32529898)
6. Hamamoto K, Hashimoto-Ninomiya A, Kishimoto Y, Kimura T, Fujitake H, Yasunaga K, Horiike S. Unbalanced 1;7 translocation in myelodysplastic syndrome following treatment of acute myeloblastic leukemia with an 8;21 translocation. Cancer Genet Cytogenet 1994;74:35-39. (Pubitemid 24176887)
7. Roulston D, Anastasi J, Rudinsky R, Nucifora G, Zeleznik-Le N, Rowley JD, McGavran L, Tsuchida M, Hayashi Y. Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases. Blood 1995; 86:3613-3614.
8. Sakai C, Matsubayashi K, Saotome T, Ishii A, Kumagai K. Therapy-related myelodysplastic syndrome with trisomy 1q due to der(1;7) and megakaryoblastic proliferation developing during complete remission of therapy-related acute myeloid leukemia with t(8;21). Intern Med 2004;43:582-586. (Pubitemid 39206698)
9. Bacher U, Schnittger S, Kern W, Trenn G, Weisser M, Haferlach T, Schoch C. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21) (q26;q22). Cancer Genet Cytogenet 2006;168:172-174.
10. Masuya M, Katayama N, Inagaki K, Miwa H, Hoshino N, Miyashita H, et al. Two independent clones in myelodysplastic syndrome following treatment of acute myeloid leukemia. Int J Hematol 2002;75:182-186. (Pubitemid 43014083)
11. Park TS, Choi JR, Yoon SH, Song J, Kim J, Kim SJ, et al. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript. Cancer Genet Cytogenet 2008; 187:61-73.
12. Qian SX, Li JY, Tian T, Shen YF, Jiang YQ, Lu H, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 2007;31:1383-1388. (Pubitemid 47212427)
13. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92:1389-1398. (Pubitemid 350144157)
14. Smith SM, Le Beau Mm, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia. Blood 2003;102:43-52. (Pubitemid 36759634)
15. Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, et al. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma 2010;51: 995-1006.
16. Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, Inoue F, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000;71:238-244.
17. Le Beau MM, Espinosa R 3rd, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996;88:1930-1935.
18. Fischer K, Fröhling S, Scherer SW, McAllister Brown J, Scholl C, et al. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood 1997;89:2036-2041.